Lucy Scientific Discovery Inc. (LSDI)

Lucy Scientific Discovery will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

Lucy Scientific Discovery is an early-stage psychotropics contract manufacturing company focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry.

In August 2021, Health Canada’s Office of Controlled Substances granted us a Controlled Drugs and Substances Dealer’s Licence. The Dealer’s Licence authorizes us to develop and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.

Since current Canadian regulations prohibit the commercial sales of APIs and other products we intend to produce, APIs and other products we intend to produce would only be authorized for sale in Canada for clinical testing purposes in an “institution,” for the purpose of determining the hazards and efficacy of the drug, and for laboratory research in an institution by qualified investigators.

As of the date of our prospectus, we have not manufactured any psychedelics-based products or generated any revenues from the sale of such psychedelics-based products.

Lucy Scientific Discovery Inc.
Country Canada
Founded 2017
Industry Health Care
Sector Pharmaceuticals
CEO Christopher McElvany

Contact Details

301-1321 Blanshard Street
Victoria, BC V8W 0B6
Phone (778) 410-5195

Stock Details

Ticker Symbol LSDI
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency US Dollars
CIK Code 1865127

Key Executives

Name Position
Christopher McElvany President, Chief Executive Officer, Chair and Director
Steven E. Meyer Chief Operating Officer
Assad J. Kazeminy, Ph.D. Chief Scientific Officer
Jerald D. Heise, Ph.D. Chief Technology Officer
Brian Zasitko CPA, CA Interim Chief Financial Officer
Paul Abramowitz Director
Brittany Kaiser Director
Sonia Luna Director
Charles B. Nemeroff, M.D., Ph.D. Director

Latest SEC Filings

Date Type Title
Mar 4, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Jan 21, 2022 S-1 General form for registration of securities under the Securities Act of 1933
Sep 27, 2021 DRS Draft Registration Statement